Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Pfizer acquired both Xtandi and Talzenna, a PARP inhibitor, in its $14 billion buyout of Medivation in 2016.
And in its Phase III TALAPRO-2 study, it combined the two drugs to treat patients with metastatic castration-resistant prostate cancer, or mCRPC for short, comparing them to Xtandi alone. Tuesday morning, Pfizer said that study met its primary endpoint of progression free survival, getting a lower hazard ratio than its pre-specified one of 0.696. But it didn’t give many more details.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.